-
Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease, with lupus nephritis (LN) affecting up to 60% of patients. Early diagnosis and treatment are critical for preserving kidney function. In a Review recently published in AJKD, the authors discuss current and emerging therapies for proliferative and membranous LN with a focus on strategies targeting underlying mechanisms of disease in LN. AJKDBlog’s Interviews Editor, Timothy Yau chatted with authors Niraj B. Desai, [...]
-
SPECIAL ANNOUNCEMENT: This entire issue will be freely available until May 30, 2026 in celebration of the NKF Spring Clinical Meeting Editor’s Note: We asked authors of Original Investigations to provide short plain-language summaries that would briefly summarize what inspired their study, the basic approach taken, what was learned, and why it matters. We hope our readers will find this valuable in helping them keep up with the latest research in the field of nephrology. Highlights from [...]
-
The NephMadness Court of Champions is welcoming a 14th member: B-cell Modulators This year entries continued to reflect the general decline in social media popularity… … while international entries stayed pretty steady. As usual, NephMadness 2026 required the talent, effort, and time of an extensive team. These folks make it all possible! We’d like to take this opportunity to recognize their contributions (with apologies to anyone we may have inadvertently missed): Blue [...]
-
NephMadness 2026 is over, and as usual we saw our fair share of buzzer beaters, upsets, and Cinderella stories. Team B-cell Modulators from the IgA Nephropathy Region emerged from a crowded field as the new champion, and its ascendance was good news for our new set of winners! Grand Prizes Each Grand Prize individual winner will receive a one-year online subscription to Advances in Kidney Disease and Health and Nature Reviews Nephrology. TOP OVERALL SCORE: Santiago Moreno Tobón Dr Moreno [...]
-
It’s all been building to this; the Blue Ribbon Panel has decreed a new NephMadness champion for 2026! Check out the Final Standings and share your reactions with #NephMadness! Many thanks to Krithika Mohan @krithicism for the scoreboard graphics! Team C3G Treatment had a magical run, but finally ran out of steam. Team B-cell Modulators’ strong offense dominated the final match up. Team B-cell Modulator with the easy win. B-cell Modulators wins 7-2 Comments from the BRP: [...]
Follow Blog by Email:
NephMadness 2026
-
NephMadness#NephMadness 2026: The Filtered Four
-
NephMadness#NephMadness 2026: IgA Nephropathy Region
-
NephMadness#NephMadness 2026: C3G – Treatments Look Poised to Win it All, A Massive Victory for Patients
-
NephMadness#NephMadness 2026: Meet the Gamemakers
-
NephMadness#NephMadness 2026: The PodCrawl
-
NephMadnessA Look Back at Top #NephMadness Regions
-
NephMadness#NephMadness 2026: Genetics – May the Best Gene Win
-
NephMadness#NephMadness 2026: Logo Reveal
Atlas of Renal Pathology II
-
Atlas of Renal Pathology IIAJKD Atlas of Renal Pathology: Light Chain Cast Nephropathy
-
Atlas of Renal Pathology IIAtlas: Clinical Quiz 5
-
Atlas of Renal Pathology IIRecurrent and De Novo FSGS Following Kidney Transplantation
-
Atlas of Renal Pathology IIFocal Segmental Glomerulosclerosis: Sampling Error in Misdiagnosis
-
Atlas of Renal Pathology IIAJKD Atlas of Renal Pathology II: The Ultimate Pathology Teaching Tool Has Arrived
-
Atlas of Renal Pathology IIAcute and Chronic Antibody-Mediated Rejection Represent a Continuum of Endothelial Injury Involving Multiple Immune Mechanisms
-
Atlas of Renal Pathology IIAtlas: Clinical Quiz 1
-
Atlas of Renal Pathology IIDiffuse Mesangial Sclerosis
-
Atlas of Renal Pathology IIRecurrent and De novo Posttransplant Minimal Change Disease
-
Atlas of Renal Pathology IIAtlas: Clinical Quiz 4
Follow Blog by Email:
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy
To find out more, including how to control cookies, see here: Cookie Policy







